A PYMNTS Company

23 million euros cleared for R&D of Novartis vaccines

By  |  May 8, 2012

The European Commission has cleared €23 million of proposed funding for Novartis Italy to develop vaccines in developing countries. After its assessment for R&D&I aid (research, development and innovation), the Commission has found that the support addresses a genuine market failure and stimulates research in the EU. Novartis’ project will create innovative vaccines at affordable prices. The project is also supported by the Gates Foundation and is expected to incur €76.9 million in R&D over five years.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full content: EC Press Release

     

    Related content: Revision of the EU Competition Rules on Cooperation in Research & Development and Production: Scope for Further Improvement (Axel Gutermuth, Arnold & Porter)

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.